

# Mucocutaneous adverse effects following COVID-19 vaccination: a case series with a comprehensive review of the literature

Parvaneh Hatami, MD <sup>1</sup>  
 Zeinab Aryanian, MD <sup>1,2</sup>  
 Hamed Niknam Asl, MD <sup>3</sup>  
 Azadeh Goodarzi, MD <sup>4\*</sup>

1. *Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran*
2. *Department of Dermatology, Babol University of Medical Sciences, Babol, Iran*
3. *Department of Dentistry, Rafsanjan University of Medical Sciences (IUMS), Rafsanjan, Iran*
4. *Department of Dermatology, Rasool Akram Medical Complex, Iran University of Medical Sciences (IUMS), Tehran, Iran*

\*Corresponding author:  
 Azadeh Goodarzi, MD  
 Department of Dermatology, Rasool Akram Medical Complex, Iran University of Medical Sciences (IUMS), Tehran, Iran  
 Email: [goodarzi.a@iums.ac.ir](mailto:goodarzi.a@iums.ac.ir), [azadeh\\_goodarzi1984@yahoo.com](mailto:azadeh_goodarzi1984@yahoo.com)

Received: 18 October 2021  
 Accepted: 30 November 2021

Since coronavirus disease 2019 (COVID-19) vaccines were approved without long-term monitoring, tracking their adverse effects appears to be necessary. Mucocutaneous adverse events are of great importance due to their visibility and the potential effect on inducing fear in patients leading to vaccine hesitancy.

We searched PubMed, Google Scholar, and Scopus in this regard, and all of the relevant papers published until June 28, 2021, were included if we could access their full texts. Moreover, we included some of our cases from Iran.

We found various mucocutaneous manifestations after COVID-19 vaccination, including local injection site reactions (acute or delayed), urticarial lesions, pityriasis rosea-like rashes, angioedema, morbilliform rashes, pernio-like lesions, acrocyanosis, petechial/purpuric/ecchymotic lesions, herpes flare-up, herpeticiform rashes, oral erosive lesions, acral pustular rashes, erythema multiform, dermatographism, herpes zoster, generalized pruritus, contact dermatitis, reaction to dermal fillers and non-specific rashes. We categorized them by their time of initiation (acute or delayed) and site of involvement (local injection site, remote area, or generalized).

Delayed local reactions, local injection site reactions, urticarial lesions, and pityriasis rosea-like and morbilliform rashes were among the most common cutaneous adverse events.

Dermatologists should be aware of these potential reactions to manage them properly, reassure patients, and encourage them to continue their vaccination.

**Keywords:** COVID-19 vaccine, angioedema, pruritus, pityriasis rosea

Iran J Dermatol 2021; 24: 331-338

DOI: [10.22034/ijd.2021.311094.1451](https://doi.org/10.22034/ijd.2021.311094.1451)

## WHAT IS KNOWN?

SARS-COV2 vaccines were approved without long-term monitoring due to the emergent situation. Hence, monitoring their adverse effects appears to be necessary.

Several articles reported vaccine's systemic, neurologic, cardiovascular, hematologic, and

renal adverse events, but mucocutaneous adverse events are also important due to their visibility and the potential effect on inducing fear in affected individuals, leading to vaccine hesitancy.

## What does this study add?

In contrast to some important systemic adverse

effects of COVID-19 vaccines, mucocutaneous reactions are usually minor and self-limited. We recommend a strict work-up, management, and follow-up of the patients with unusual dermatologic signs like patients with targetoid vesiculobullous, erosive cutaneous or mucosal lesions, or multiple/generalized petechia-purpuric/ecchymotic lesions.

Dermatologists should be aware of these potential reactions to manage them properly, reassure patients, and encourage them to continue their vaccination.

## INTRODUCTION

The coronavirus disease 2019 (COVID-19) pandemic posed a significant burden on healthcare systems worldwide and made the year 2020 the most challenging year in this regard. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines were approved without long-term monitoring due to the emergent situation. Hence, monitoring their adverse effects appears to be necessary.

Several articles reported vaccine's systemic, neurologic, cardiovascular, hematologic, and renal adverse events<sup>1-4</sup>, but mucocutaneous adverse events are also important due to their visibility and the potential effect on inducing fear in affected individuals, leading to vaccine hesitancy.

Here, we present dermatologists with an overview of the mucocutaneous adverse events reported following COVID-19 vaccination to obtain a better insight in this regard. The authors of this study have dealt with various aspects of COVID-19 during the pandemic, especially certain dermatologic concerns and hot topics. In this regard, they tried to collect all necessary and related data of their practice. Now, they believe that mucocutaneous reactions of the COVID-19 vaccine are among the most important dermatologic issues of the pandemic. They present some original pictures of their patients with different dermatologic signs and symptoms probably related to recent vaccinations.

## PARTICIPANTS AND METHODS

We presented six patients with mucocutaneous presentations after COVID-19 vaccination from Iran and searched PubMed, Google Scholar, and Scopus in this regard. All of the relevant papers published

until June 28, 2021, were included if we could access their full texts. Studies in languages other than English were not included. The following keywords were used for the search: COVID-19 vaccine, Vaccine, Adverse effects, Side effect, Cutaneous, Mucocutaneous, Mucosal, Dermatology, Moderna, Pfizer, Sputnik, Bharat, AstraZeneca, Sinopharm, delayed-type hypersensitivity, SARS-CoV-2, adverse event, local site reaction, injection site reaction, remote site reaction, acute, late, delayed, pityriasis rosea, urticaria, angioedema, maculopapular rash, morbilliform rash, exanthematous rash, petechia, purpura, ecchymosis, pruritus, erythema multiforme, herpes, zoster, pernio, cyanosis, edema

## RESULTS

The reported dermatology-related adverse events of the COVID-19 vaccine are summarized in Table 1. We divided these reactions into localized and generalized, and in each group, we considered < 24 hours as acute and > 24 hours as a delayed reaction. We also present our six patients, whose eruptions are shown in Figures 1-6. These reactions were pityriasis rosea, urticaria, erythema multiform, generalized petechia, purpura, and ecchymosis.

## DISCUSSION

As seen with other vaccines, the most prevalent dermatologic reactions after COVID-19 vaccination are localized erythema, tenderness, and swelling<sup>5,6</sup>.

In an observational cohort study of hospital workers in California, 1.1% of female participants who received the first dose of mRNA-1273 SARS-CoV-2 (Moderna) vaccine developed a delayed-onset pruritic rash at the injection site, and about half of them developed this rash even earlier after receiving the second dose<sup>5</sup>. In that study, none of the employees receiving BNT162b (Pfizer) reported such reactions. Interestingly, this rash was seen only in female cases. Since that study was based on self-reported data, it is possible that many healthcare professionals, especially men, may not consider the rash important enough to report. However, some studies indicate that women are at a greater risk for adverse drug reactions<sup>6</sup>, and several hypotheses such as sex-based differences in pharmacodynamics and different body mass indexes

**Table 1.** Mucocutaneous adverse effects of COVID-19 vaccine

<b>Local lesions</b>	
Acute (<24h)	
Injection site	
	McMahon <i>et al.</i> <sup>6</sup> (second most common reaction)
	Baden <i>et al.</i> <sup>43</sup> (most common reaction)
	Jęśkowiak <i>et al.</i> <sup>1</sup> (most common reaction)
Remote site	
	Angioedema (lips and acral)
Delayed (>24h)	
Injection Site	
	McMahon <i>et al.</i> <sup>6</sup> (most common reaction)
	Jacobson <i>et al.</i> <sup>5</sup> (most common reaction, seen only in women)
	Johnston <i>et al.</i> <sup>44</sup> (reported "COVID-19 arm" in 16 patients)
Remote site	
Filler	
	Munavalli <i>et al.</i> <sup>15</sup> (DIR to fillers, rapid response to ACEI)
Perniosis, acrocyanosis	
	Kha <i>et al.</i> <sup>45</sup> (reported a case of perniosis two days after vaccination)
Contact dermatitis	
	Baden <i>et al.</i> <sup>43</sup> (third most common reaction)
Others	
	Erythromelalgia, dermographism, EM, acral pustular rash, herpes flare-up, erosive oral lesions, varicella-zoster
<b>Generalized lesions</b>	
Acute (<24h)	
Petechial rash	
	Cebeci <i>et al.</i> <sup>46</sup> (an 82-year-old woman with petechial rash on her feet 10 hours after vaccination)
Delayed (>24h)	
Urticarial	
	McMahon <i>et al.</i> <sup>6</sup> (third most common reaction)
	Baden <i>et al.</i> <sup>43</sup> (second most common reaction)
Pityriasis Rosea	
	McMahon <i>et al.</i> <sup>6</sup>
Generalized pruritus	
	Authors' experience
Morbilliform Rash	
	McMahon <i>et al.</i> <sup>6</sup> (fourth most common reaction)
Non-specific rash	
	McMahon <i>et al.</i> <sup>6</sup> (reported non-specific rashes in infants of breastfeeding women who received vaccine)

Abbreviations: DIR, delayed inflammatory reaction; ACEI, angiotensin-converting enzyme inhibitor; EM: erythema multiforme

have been raised as potential explanations <sup>7,8</sup>. Since this delayed-type hypersensitivity-based reaction was only seen in the Moderna vaccine, one can infer that the Moderna vaccine might have more immunogenic ability than the Pfizer vaccine, but more studies are needed to shed some light on this issue.

Another study recorded 414 cases of mucocutaneous reactions following vaccination with the Moderna and Pfizer COVID-19 vaccines from December 2020 to February 2021. Of those, 83% received Moderna and 17% Pfizer. Delayed local reactions, local injection site reactions,

urticaria, and morbilliform rash were the most common dermatologic adverse events in the order stated <sup>6</sup>. Moreover, about half of the patients with mucocutaneous reactions experienced an earlier recurrence following the second dose of the vaccine, consistent with Jacobson *et al.* <sup>5</sup>. Though the exact etiology of this delayed-type reaction (DTR) after the Moderna vaccine is not clear, hypersensitivity to polyethylene glycol used as an excipient in the vaccine is considered a potential etiology <sup>9</sup>. This hypothesis can be tested in future studies by checking the affected individuals regarding their positive history of hypersensitivity to other products



**Figure 1.** Generalized pityriasis rosea 3-4 weeks after vaccination in two young women



**Figure 2.** Generalized urticaria after the second dose of vaccine



**Figure 3.** Erythema multiform-like lesions a few weeks after vaccination in a young woman vaccinated in another country before traveling to Iran. The patient simultaneously had extensive erosive mucosal lesions



**Figure 4.** Multiple ecchymotic and purpuric lesions in association with generalized pruritus in a young woman without any history of trauma that had a resolving course within 1-2 weeks without any treatment



**Figure 6.** Palpable purpura with a histologic diagnosis of vasculitis in a 69-year-old man with pemphigus vulgaris appearing one week after vaccination



**Figure 5.** Acral pustular lesions in a 72-year-old woman appearing two weeks after vaccination

containing polyethylene glycol such as penicillin, injected corticosteroids, laxatives, antacids, and some chemotherapy medications<sup>10,11</sup> or simply by implementing a patch test.

This delayed inflammatory reaction was also seen in a few patients with a history of filler injection<sup>12-16</sup>. Munavalli *et al.* reported 4 cases with DTR to hyaluronic acid filler occurring rapidly within 24 to 48 hours following the first or second dose of COVID-19 vaccines<sup>15</sup>. Since all of these reported cases received their fillers more than eight months before, it is hypothesized that the breakdown of residual filler, which occurs within 3-5 months<sup>14</sup>, generates short-chain hyaluronic acid molecules that might be responsible for this reaction<sup>15</sup>. This low-molecular-weight hyaluronic acid, perhaps with biofilms<sup>12,13</sup>, might play an important role in developing pre-granuloma milieu and a CD8+ immune response<sup>12</sup>. Furthermore, the FDA brief on the SARS-CoV-2 Moderna vaccine reported three cases with reaction to dermal fillers, out of which one had filler injection only two weeks

before vaccination<sup>16</sup>. Accordingly, it is impossible to consider filler breakdown as the only mechanism responsible for the reaction to fillers triggered by the vaccine. Genetic susceptibility, HLA subtypes B\*08 and DRB1\*03, abnormalities in fibrinogen, C-reactive protein, and low complement levels might play a role in this reaction<sup>17-19</sup>.

Some resident cutaneous cells such as fibroblasts and lymphocytes have angiotensin-converting enzyme receptors (ACE2), the target ligand for the SARS-CoV-2 spike protein<sup>20</sup>. This might explain the capability of ACE inhibitors in providing rapid clinical resolution seen in DTR<sup>15</sup>. Other therapeutic options include a short course of oral steroids (less than two weeks; does not appear to negatively impact vaccine efficacy), oral antihistamines, and even hyaluronidase for prolonged reactions<sup>14,21,22</sup>. ACE inhibitors might be initiated prophylactically before vaccination to prevent DTR in concerned people with a history of long-lasting dermal fillers or before the second dose of vaccine in those with a history of DTR after the first dose<sup>15</sup>. Another prophylactic measure might be the dilution of hyaluronic acid with lidocaine, saline, or sterile water to reduce the risk of DTR<sup>23,24</sup>.

Some less common mucocutaneous adverse effects reported following COVID-19 vaccination include erythromelalgia, pernio/chilblain, pityriasis rosea-like exanthema, herpes simplex flares, varicella-zoster, and non-specific rashes in infants of breastfeeding women<sup>6,25</sup>. Some of them have also been reported following the SARS-CoV-2 infection itself<sup>26,27</sup>, reflecting the role of the immune system in presenting these manifestations rather than a direct effect of the virus<sup>28</sup>.

A summary of the findings of the studies mentioned above is presented in Table 1.

Since vaccination for COVID-19 began in Iran, the authors of this study have encountered some non-critical and self-limited mucocutaneous reactions, most of which were related to a vaccination history of COVID-19 a few weeks before dermatologic presentations. These eruptions included exanthematous morbilliform maculopapular rashes, symptomatic dermatographism, urticaria and angioedema, pityriasis rosea, multiple petechial/purpuric and ecchymotic lesions, generalized pruritus, erythema multiforme, erosive herpetic oral mucosal lesions or herpetic or herpeticiform skin lesions, non-specific papular eruptions, pernio-like

lesions, mild acral cyanosis, acral pustular eruptions and acute acral edema observed in our outpatient clinic. Six patients are presented here, and their eruptions are shown in Figures 1-6.

In our short experience with probable COVID-19 vaccine-associated mucocutaneous presentations, most of the reactions were typical rosea-like lesions and even a few atypical forms, symptomatic dermatographism, generalized urticaria, non-critical angioedema, and non-specific maculopapular exanthems. Other mentioned signs and symptoms were observed with a lower prevalence. We experienced that almost all of these dermatologic presentations were non-critical and self-limited, but it appears necessary to discuss possible less common and rare critical or potentially life-threatening reactions to increase the body of knowledge in this field, and to publish more reports of vaccine-associated side effects. It was surprising that most of our observations about mucocutaneous eruptions of the COVID-19 vaccine occurred in women, especially young women.

The authors of this study have focused on hot topics of COVID-19 research during the pandemic<sup>27,29-42</sup> and now turned their focus on mucocutaneous eruptions associated with the COVID-19 vaccine as an issue of great importance discussed in this paper. Some of these presentations occurred within one to six weeks after vaccination with various types of COVID-19 vaccines. Most of these mucocutaneous presentations emerged about three to four weeks after vaccination. These patients did not have any other recent medical history that could be related to these dermatologic signs and symptoms other than the COVID-19 vaccination history.

## CONCLUSION

In conclusion, in contrast to some important systemic adverse effects of COVID-19 vaccines, mucocutaneous reactions are usually minor and self-limited. Dermatologists should be aware of these potential reactions to properly manage them, reassure patients, and encourage them to continue their vaccination. It is needed to know more about COVID-19 vaccines-associated dermatologic reactions during a time, especially considering the high rate of these types of reactions worldwide. Logically among them, we

may encounter some rare but important and even life-threatening reactions that should be better studied and managed. We recommend a strict work-up, management, and follow-up of patients with rare and unusual dermatologic signs like patients with targetoid vesiculobullous lesions, erosive cutaneous or mucosal lesions, or multiple/generalized petechia-purpuric/ecchymotic lesions. In the future perspective of COVID-19 adverse effects in the field of dermatology, it is of great value to systematically review these eruptions, especially to distinguish non-critical from critical reactions, risk factors of critical reactions, the impact of immune system status on probable vaccine adverse effects like any severity changes of reactions in immunocompromised patients or patients with certain dermatologic disorders under treatment with immunomodulator medications.

### Acknowledgment

The authors would like to thank Rasool Akram Medical Complex Clinical Research Development Center (RCRDC) for its technical and editorial assistance.

**Conflict of Interests:** None declared.

### Study approval

Any aspect of the work that has involved human patients was conducted after obtaining the ethical approval of all relevant bodies.

### REFERENCES

- Jęśkowiak I, Wiatrak B, Grosman-Dziewiszek P, et al. The incidence and severity of post-vaccination reactions after vaccination against COVID-19. *Vaccines*. 2021;9(5):502.
- Román GC, Gracia F, Torres A, et al. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222). *Front Immunol*. 2021;12:879.
- Rzymiski P, Perek B, Flisiak R. Thrombotic thrombocytopenia after COVID-19 vaccination: in search of the underlying mechanism. *Vaccines*. 2021;9(6):559.
- Tang LV, Hu Y. Hemophagocytic lymphohistiocytosis after COVID-19 vaccination. *J Hematol Oncol*. 2021;14(1):1-5.
- Jacobson MA, Zakaria A, Maung Z, et al. Incidence and characteristics of delayed injection site reaction to the mRNA-1273 SARS-CoV2 vaccine (Moderna) in a cohort of hospital employees. *Clin Infect Dis*. 2021.
- McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. *J Am Acad Dermatol*. 2021;85(1):46-55.
- de Vries ST, Denig P, Ekhart C, et al. Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: an explorative observational study. *Br J Clin Pharmacol*. 2019;85(7):1507-15.
- Rademaker M. Do women have more adverse drug reactions? *Am J Clin Dermatol*. 2001;2(6):349-51.
- Banerji A, Wickner PG, Saff R, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: Current evidence and approach. *J Allergy Clin Immunol Pract*. 2020.
- Damiano Monticelli VM, Mocchi R, Rauso R, et al. Chemical characterization of hydrogels crosslinked with polyethylene glycol for soft tissue augmentation. *Open Access Maced J Med Sci*. 2019;7(7):1077.
- Garvey LH, Nasser S. Anaphylaxis to the first COVID-19 vaccine: Is polyethylene glycol (PEG) the culprit? *Br J Anaesth*. 2020.
- Alijotas-Reig J, Fernández-Figueras MT, Puig L. Late-onset inflammatory adverse reactions related to soft tissue filler injections. *Clin Rev Allergy Immunol*. 2013;45(1):97-108.
- Artzi O, Cohen JL, Dover JS, et al. Delayed inflammatory reactions to hyaluronic acid fillers: a literature review and proposed treatment algorithm. *Clin Cosmet Investig Dermatol*. 2020;13:371.
- Beleznay K, Carruthers JD, Carruthers A, et al. Delayed-onset nodules secondary to a smooth cohesive 20 mg/mL hyaluronic acid filler: Cause and management. *Dermatol Surg*. 2015;41(8):929-39.
- Munavalli GG, Knutsen-Larson S, Lupo MP, et al. Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination—a model for inhibition of angiotensin II-induced cutaneous inflammation. *JAAD Case Rep*. 2021;10:63-8.
- Zhang R, editor FDA presentation and voting questions. US food and drug administration. Center for biologics evaluation and research, 163rd meeting of the vaccines and related biological products. Advisory Committee Silver Spring, MD; 2020.
- Alijotas-Reig J, Esteve-Valverde E, Gil-Aliberas N, et al. Autoimmune/inflammatory syndrome induced by adjuvants—ASIA—related to biomaterials: analysis of 45 cases and comprehensive review of the literature. *Immunol Res*. 2018;66(1):120-40.
- Alijotas-Reig J, Garcia-Gimenez V. Delayed immune-mediated adverse effects related to hyaluronic acid and acrylic hydrogel dermal fillers: clinical findings, long-term follow-up and review of the literature. *J Eur Acad Dermatol Venereol*. 2008;22(2):150-61.
- Decates TS, Velthuis PJ, Schelke LW, et al. Increased risk of late-onset, immune-mediated, adverse reactions related to dermal fillers in patients bearing HLA-B\* 08 and DRB1\*

- 03 haplotypes. *Dermatol Ther.* 2020:e14644.
20. Steckelings UM, Wollschläger T, Peters J, et al. Human skin: source of and target organ for angiotensin II. *Exp Dermatol.* 2004;13(3):148-54.
  21. Pathmanathan S, Dzienis M. Cetuximab associated dermal filler reaction. *BMJ Case Reports CP.* 2019;12(8):e228882.
  22. Turkmani MG, De Boule K, Philipp-Dormston WG. Delayed hypersensitivity reaction to hyaluronic acid dermal filler following influenza-like illness. *Clin Cosmet Investig Dermatol.* 2019;12:277.
  23. Lemperle G, Romano JJ, Busso M. Soft tissue augmentation with Artecoll: 10-year history, indications, techniques, and complications. *Dermatol Surg.* 2003;29(6):573-87.
  24. Lowe NJ, Maxwell CA, Patnaik R. Adverse reactions to dermal fillers. *Dermatol Surg.* 2005;31:1626-33.
  25. Arora P, Sardana K, Mathachan SR, et al. Herpes zoster after inactivated COVID-19 vaccine: a cutaneous adverse effect of the vaccine. *J Cosmet Dermatol.* 2021.
  26. Galván Casas C, Catala A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. *Br J of Dermatol.* 2020;183(1):71-7.
  27. Seirafianpour F, Sodagar S, Pour Mohammad A, et al. Cutaneous manifestations and considerations in COVID-19 pandemic: a systematic review. *Dermatol Ther.* 2020;33(6):e13986.
  28. Welsh E, Cardenas-de la Garza J, Cuellar-Barboza A, et al. SARS-CoV-2 spike protein positivity in pityriasis rosea-like and urticaria-like rashes of COVID-19. *Br J Dermatol.* 2021.
  29. Atefi N, Behrangi E, Mozafarpour S, et al. N-acetylcysteine and coronavirus disease 2019: May it work as a beneficial preventive and adjuvant therapy? A comprehensive review study. *J Res in Med Sci.* 2020;25(1):109.
  30. Bazargan M, Behrangi E, Goodarzi A. Cytokine storm and probable role of immunoregulatory drugs in COVID-19: a comprehensive review. *Iran J Dermatol.* 23:1.
  31. Mohamadi M, Goodarzi A, Aryannejad A, et al. Geriatric challenges in the new coronavirus disease-19 (COVID-19) pandemic: a systematic review. *Med J Islam Repub Iran.* 2020;34:123-.
  32. Najari Nobari N, Seirafianpour F, Mashayekhi F, et al. A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients. *Dermatol Ther.* 2020.
  33. Nobari NN, Goodarzi A. Patients with specific skin disorders who are affected by COVID-19: what do experiences say about management strategies? A systematic review. *Dermatol Ther.* 2020:e13867.
  34. Sadeghzadeh-Bazargan A, Behrangi E, Goodarzi A. Systemic retinoids in the COVID-19 era—are they helpful, safe, or harmful? A comprehensive systematized review. *Iran J Dermatol.* 2020;23(Suppl. 1(COVID-19)):9-12.
  35. Seirafianpour F, Mozafarpour S, Fattahi N, et al. Treatment of COVID-19 with pentoxifylline: could it be a potential adjuvant therapy? *Dermatol Ther.* 2020;33(4):e13733.
  36. Goodarzi A. A comprehensive review on COVID-19 infection and comorbidities of various organs. *Acta Medica Iranica.* 2021:4-14.
  37. Kooranifar S, Sadeghipour A, Riahi T, et al. Histopathologic survey on lung necropsy specimens of 15 patients who died from COVID-19: a large study from Iran with a high rate of anthracosis. *Med J Islam Repub Iran.* 2021;35(1):481-90.
  38. Najari Nobari N, Seirafianpour F, Dodangeh M, et al. A systematic review of the histopathologic survey on skin biopsies in patients with corona virus disease 2019 (COVID-19) who developed virus or drug-related mucocutaneous manifestations. *Exp Dermatol.* 2021.
  39. Nobari NN, Montazer F, Seirafianpour F, et al. Histopathologic changes and cellular events of organs systems in COVID-19. *J Cell Mol Anesth.* 2021;6(1):81-8.
  40. Sadeghzadeh-Bazargan A, Rezai M, Nobari NN, et al. Skin manifestations as potential symptoms of diffuse vascular injury in critical COVID-19 patients. *J Cutan Pathol.* 2021.
  41. Kalantari S S-BA, Ebrahimi S, Yassin Z, et al. The effect of influenza vaccine on severity of COVID-19 infection: an original study from Iran. *Med J Islam Repub Iran.* 2021.
  42. Riahi T, Sadeghzadeh-Bazargan A, Shokri S, et al. The effect of opium on severity of COVID-19 infection: an original study from Iran. *Med J Islam Repub Iran.* 2021.
  43. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *New England J Med.* 2021;384(5):403-16.
  44. Johnston MS, Galan A, Watsky KL, et al. Delayed localized hypersensitivity reactions to the Moderna COVID-19 vaccine: A case series. *JAMA Dermatol.* 2021.
  45. Kha C, Itkin A. New-onset chilblains in close temporal association to mRNA-1273 (Moderna) vaccination. *JAAD Case Rep.* 2021.
  46. Cebeci F, Kartal İ. Petechial skin rash associated with CoronaVac vaccination: First cutaneous side effect report before phase 3 results. *Eur J Hospital Pharm.* 2021.